Insulin before ChemoTherapy

Dr. Weeks’ Comment: Insulin lowers blood sugar so giving it IV before introducing chemotherapy can potentiate the effect of the chemotherapy. This is powerful for all cancers, not just prostate cancer.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357525/

ISRN Urol. 2012; 2012: 140182. Published online 2012 May 8. doi: 10.5402/2012/140182PMCID: PMC3357525PMID: 22649741

Low-Dose Chemotherapy with Insulin (Insulin Potentiation Therapy) in Combination with Hormone Therapy for Treatment of Castration-Resistant Prostate Cancer

1. ABSTRACT


Purpose
. To evaluate the results and quality of life of patients with resistant of castration-resistant tumors previously treated with Insulin-potentiation therapy (IPT) combined with hormone therapy. Materials and methods. Sixteen patients with metastasis prostate tumors after bilateral castration, androgenic blockade, and progression of the disease were observed during the study. The patients were divided into two groups: group A consisting of 8 patients treated with low-dose chemotherapy Epirubicin, Vinblastine, and Cyclophosphamide combined with LHRH agonist and group B consisting of another 8 patients treated with low-dose chemotherapy Docetaxel combined with LHRH agonist. Results. The overall (groups A and B) results concerning PSA after the sixth IPT show partial effect in 8 out of 16 (50%) patients, stabilization in 4 out of 16 (25%), and progression in 4 out of 16 (25%). The median survival for all treated patients is 11,7 months (range 3–30 months). During the treatment no significant side effects were observed, and no lethal cases occurred. Conclusion. In spite of the small number of the treated patients with castration-resistant prostate tumors, the preliminary results are promising and this gives us hope and expectations for future serious multicenter research over the possibilities for routine implementation of IPTLD.

6. Conclusion

Our present experience with IPTLD (in more than 400 treated patients) with various tumors as well as the practical experience of the growing number of doctors practicing the method gives us a reason to assume that IPTLD method provides a real opportunity for resolving one of the most serious problems of toxicity associated with chemotherapy using maximum tolerated doses. A certain advantage of the method along with its effectiveness is the significantly improved quality of life of the treated patients.

In spite of the small number of patients treated by us with castrate-resistant prostate tumor, the preliminary results are promising and this gives us hope and expectations for future serious researches on the potential of widespread clinical use of IPTLD.